Your browser doesn't support javascript.
loading
A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder.
Wagg, Adrian S; Herschorn, Sender; Carlsson, Martin; Fernet, Mireille; Oelke, Matthias.
Afiliación
  • Wagg AS; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Herschorn S; Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
  • Carlsson M; Statistics Lead-Rare Disease/Endocrine, Pfizer Global Product Development, New York, New York, USA.
  • Fernet M; Medical Affairs/Affaires Médicales, Pfizer Canada, Montreal, Quebec, Canada.
  • Oelke M; Department of Urology, St. Antonius-Hospital, Gronau, Germany.
J Comp Eff Res ; 11(13): 919-925, 2022 09.
Article en En | MEDLINE | ID: mdl-35881009
WHAT IS THIS SUMMARY ABOUT?: This is a summary of a study originally published in Neurourology and Urodynamics. Overactive bladder is a medical condition that causes an urgent need to urinate, which can cause accidental urination. Fesoterodine is a medication used to treat overactive bladder. Because we don't know how likely it is that an individual patient will achieve a level of improvement in their overactive bladder symptoms, researchers analyzed results of 6 studies of patients with overactive bladder who were treated with fesoterodine. WHAT WERE THE RESULTS?: Although complete resolution of all symptoms was rare with fesoterodine treatment, a resolution of accidental urination was more common, which is the most important treatment goal for many patients. After taking fesoterodine, episodes of accidental urination were more likely to be reduced or completely absent than episodes of an urgent need to urinate. WHAT DO THE RESULTS OF THE STUDY MEAN?: These results can help patients with overactive bladder understand their own chances of treatment success with fesoterodine and can help doctors support their patients on what to expect regarding their specific symptoms and concerns. ▪Toviaz (fesoterodine) is approved to treat the condition that is discussed in this summary. Approval varies from country to country; please check with your local health provider for more details. ▪This summary reports the combined results of 6 studies. The results of individual studies may vary from the combined study results presented here. Individuals should make treatment decisions based on all available evidence. ClinicalTrials.gov NCT number: NCT01302054, NCT01302067, NCT00444925, NCT00611026, NCT00220363, and NCT00138723.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vejiga Urinaria Hiperactiva Tipo de estudio: Diagnostic_studies / Prognostic_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: J Comp Eff Res Año: 2022 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vejiga Urinaria Hiperactiva Tipo de estudio: Diagnostic_studies / Prognostic_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: J Comp Eff Res Año: 2022 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido